Skip to main content
Martin Farlow, MD, Neurology, Indianapolis, IN

Martin R Farlow MD


Professor and Vice Chairman of Research, Department of Neurology; Core Leader, IADC Clinical Core

Join to View Full Profile
  • 550 University BlvdIndianapolis, IN 46202

  • Phone+1 317-274-8800

Dr. Farlow is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Indiana University School of Medicine
    Indiana University School of MedicineResidency, Neurology, 1980 - 1983
  • Indiana University School of Medicine
    Indiana University School of MedicineInternship, Internal Medicine, 1979 - 1980
  • Indiana University School of Medicine
    Indiana University School of MedicineClass of 1979

Certifications & Licensure

  • IN State Medical License
    IN State Medical License 1979 - 2025
  • Neurology
    American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2003-2014
  • Indianapolis Monthly Castle Connolly, 2007, 2009, 2011, 2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and Treatment  
    Jared R. Brosch, Martin R. Farlow, Neurology and Therapy
  • The Cholinergic System in the Pathophysiology and Treatment of Alzheimer’s Disease  
    George T Grossberg, Peter J Snyder, Martin R Farlow, Brain

Lectures

  • The Treatment of Alzheimer’s Disease: Comparing Guidelines 
    162nd Annual Meeting, San Francisco, California, USA
  • Severe Alzheimer Disease Responds Well to the 13.6 mg/24 hour Versus the 4.6 mg/24 hour Rivastigmine Patch 
    166th Annual Meeting, San Francisco, California, USA
  • The Treatment of Alzheimer’s Disease: Comparing Guidelines 
    American Psychiatric Association, 162nd Annual Meeting, San Francisco, California, USA
  • Join now to see all

Other

Press Mentions

  • Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease
    Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s DiseaseOctober 4th, 2022
  • Annovis Bio Inc. (ANVS) Stock Plunged During Current Market. Here’s the Update
    Annovis Bio Inc. (ANVS) Stock Plunged During Current Market. Here’s the UpdateJuly 29th, 2021
  • NervGen Pharma : Expands Alzheimer's Disease Scientific Advisory Board
    NervGen Pharma : Expands Alzheimer's Disease Scientific Advisory BoardJuly 12th, 2021
  • Join now to see all

Grant Support

  • Multi-center development of a novel diagnostic test for Alzheimer's diseaseBOSTON UNIVERSITY MEDICAL CAMPUS2018–2025
  • Core--ClinicalNational Institute On Aging2006–2010
  • Study Of AIT 082 In Mild Alzheimer'S Disease PatientsNational Center For Research Resources2000–2002
  • Core-- ClinicalNational Institute On Aging1994–2002
  • Ndd094 In 3 Cohorts For Mild To Moderate Alzheimers DiseaseNational Center For Research Resources1999
  • Phase I Study Of AIT 082 In Healthly Elderly VolunteersNational Center For Research Resources1998–1999

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: